aTyr Pharma Inc

NASDAQ:ATYRUnited States

aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).

Contact Information

Headquarters

10240 Sorrento Valley Road, Suite 300SAN DIEGO, CA, United States 92121

Phone

858-731-8389

Fax

858-731-8394

Executives

Independent Chairman of the Board

Timothy Coughlin

President, Chief Executive Officer, Director

Sanjay Shukla

Chief Financial Officer

Jill Broadfoot

General Counsel, Corporate Secretary

Nancy Denyes

Independent Director

John Clarke